ArticleFrontiers in oncology2024

A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL).

Alessandro Cafaro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.